Skip to main content

news

 

Clifford Chance and Nishimura & Asahi have acted for private equity firm CVC Capital Partners on its 17-billion-yen ($1.2 billion) acquisition of Sogo Medical Group, Japan’s fifth-biggest pharmacy by store numbers, from Polaris Capital Group. Sogo and Polaris were represented by Mori Hamada & Matsumoto.

Tokyo-based private equity fund Polaris took Sogo Medical private in a near-100 billion yen management buyout in 2020, Reuters reported, adding that CVC aims for an early re-listing of the Japanese pharmacy chain through expansionary M&As.

“Over the years, Sogo has also developed an extensive network of approximately 740 pharmacies nationwide, including the medical malls developed and operated by Sogo to better address local healthcare provision issues” amid Japan’s ageing population, said CVC in a statement. “With the transfer of ownership to CVC Asia V, Sogo will continue to focus on key initiatives to provide high value-added functions and services to both medical institutions and patients.”

The Clifford Chance team, which advised on the anti-trust aspect of the deal, was led by partner Michihiro Nishi.

White & Case advised CVC on the financing for the transaction. The team was led by partners Clara Shirota and Naoya Shiota. 

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Cleary, A&O Shearman advise on Goodyear's $701 mln Dunlop sale

Cleary Gottlieb has advised tyremaker Goodyear Tire & Rubber Company on the $701 million sale of its Dunlop brand to Japan's Sumitomo Rubber Industries (SRI), which was represented by A&O Shearman.

Mori Hamada, Nagashima Ohno advise on $1.6 bln bid for Fujitsu General

Japanese law firms Mori Hamada & Matsumoto and Nagashima Ohno & Tsunematsu are playing key roles in Paloma Rheem Holdings' 257 billion yen ($1.6 billion) offer to acquire air conditioner manufacturer Fujitsu General.

CAM, Khaitan, Linklaters act on $355 mln Sai Life Sciences IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has driven the $355 million initial public offering of TPG-backed Indian healthcare R&D firm Sai Life Sciences, with Khaitan & Co and Linklaters advising the bookrunning lead managers. CAM has also acted for selling promoter shareholders Sai Quest Syn.